This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About Crescent Capital BDC (CCAP) Rating Upgrade to Buy
by Zacks Equity Research
Crescent Capital BDC (CCAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Crescent Capital BDC (CCAP) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Crescent Capital BDC (CCAP) delivered earnings and revenue surprises of 6.78% and 4.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Regency Centers (REG) Surpasses Q1 FFO Estimates
by Zacks Equity Research
Regency Centers (REG) delivered FFO and revenue surprises of 3.85% and 1.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Crescent Capital BDC (CCAP) Stock Moves -1.05%: What You Should Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed at $17 in the latest trading session, marking a -1.05% move from the prior day.
Is It Worth Investing in Crescent Capital BDC (CCAP) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Crescent Capital BDC (CCAP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Crescent Capital BDC (CCAP) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed at $17.50 in the latest trading session, marking a +0.81% move from the prior day.
Zacks Industry Outlook Highlights Bain Capital Specialty Finance, Barings BDC and Crescent Capital
by Zacks Equity Research
Bain Capital Specialty Finance, Barings BDC and Crescent Capital have been highlighted in this Industry Outlook article.
3 SBIC & Commercial Finance Stocks to Buy Amid Grim Industry Prospects
by Swayta Shah
Weak asset quality, high rates and macroeconomic woes are likely to hurt Zacks SBIC & Commercial Finance industry players like Bain Capital (BCSF), Barings BDC (BBDC) and Crescent Capital (CCAP). Yet, decent financing demand across sectors is likely to aid.
Here's Why Crescent Capital BDC (CCAP) Fell More Than Broader Market
by Zacks Equity Research
Crescent Capital BDC (CCAP) closed at $16.99 in the latest trading session, marking a -1.51% move from the prior day.
Is Crescent Capital BDC (CCAP) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Crescent Capital BDC (CCAP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?